3 results
Approved WMOCompleted
To determine the toxicity of Zirconium-89 (Zr89) labelled Cetuximab in patient with stage IV cancer.
Not approvedWill not start
Assess cognitive efficacy of gantenerumab, solanezumab in individuals who have mutations causing dominantly inherited Alzheimer's disease as measured by change in the DIAN-TU cognitive composite score between baseline and a minimum of 4 years.…
Approved WMOWill not start
Primary Objective: The primary objective of this randomized controlled study is to assess the safety and efficacy of the VITARIA* System when added to stable, guideline-directed medical therapy for patients with heart failure and reduced left…